PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of springeropenLink to Publisher's site
Pediatric Nephrology (Berlin, Germany)
 
Pediatr Nephrol. 2012 June; 27(6): 911–916.
Published online 2011 September 27. doi:  10.1007/s00467-011-1998-3
PMCID: PMC3337416

Renal tumours: long-term outcome

Abstract

Childhood cancer is rare, with an incidence of 100 new cases per million children and with renal tumours contributing 7% of cases. The introduction of multimodality treatment, surgery, radiotherapy and chemotherapy, has led to an exponential increase in the 5-year survival rate to >80%. However, this successful treatment has led to the development of late adverse effects. These treatment-related effects can cause premature deaths and increased morbidity compared with patients’ peers. Radiation causes damage to tissue and organs within the radiation field, affecting growth and function, and is largely responsible for the leading cause of death, namely, second malignant neoplasms. Another important late effect is cardiac dysfunction due to anthracycline use with or without cardiac radiation. In addition, a few patients have genetic abnormalities predisposing to Wilms tumour development, which result in renal dysfunction in the long term and may be exacerbated by cancer treatment regimens. Awareness of late consequences of cancer treatment is important, as early recognition can improve outcome. When presented with a patient with a history of renal tumours, it is vital to enquire about previous treatment to understand whether it is relevant to the presenting problem.

Keywords: Childhood, Renal cancer, Late effects, Survivorship
Keywords: Medicine & Public Health, Pediatrics

Introduction

Childhood cancer is rare, with an incidence of 100 new cases per million children and with renal tumours contributing 7% of cases: approximately 100 new cases per year. There are several different types of renal tumours diagnosed during childhood, both benign (mesoblastic nephroma) and malignant [Wilms tumour (WT), clear-cell sarcoma of the kidney, renal rhabdoid, renal-cell carcinoma]. By far the commonest is WT (nephroblastoma) at 85%. Therefore, the majority of long-term follow-up studies feature WT survivors. Treating renal tumours has been highly successful since the introduction of multimodality treatment, with a 5-year survival rate that has increased dramatically over the last three decades from 25% in the prechemotherapy era of the late 1960s and early 1970s, to 90% in the 1990s [1]. Treatment, by design, is cytotoxic and at present is unfocused, so that damage occurs to both cancer cells and normal tissue. The extent of the damage depends on many factors, including patient demographics, genetic factors and treatment modalities and doses required to cure the cancer. The majority of renal tumours occur in young children with WT presenting at a mean age of 3 years. These young patients are highly vulnerable to tissue damage, as the normal growth and development may be affected.

The improving survival rate extending over three decades has enabled good long-term outcome studies to be conducted, providing valuable information to inform follow-up and to improve health status for future patients. This information on treatment-related late effects comes from a variety of studies, including large epidemiological (population/multicentre) and single/multicentre studies. The use of multimodality options has been incorporated into the regimens since the 1980s and consists of surgery, chemotherapy and radiotherapy, with intensity depending on histological diagnosis, disease extent and treatment era [2]. Commonly used drugs are vincristine, actinomycin D, anthracyclines (doxorubicin) and alkylating agents (cyclophosphamide, ifosphamide). More recent protocols incorporate carboplatin and etoposide in high-risk patients. Radiotherapy is prescribed if the disease is outside the resected kidney or there is metastatic disease, which is usually confined to the lungs. The total radiation dose and fractionation (daily dose) has changed over the years in an attempt to reduce late effects. Lower total radiation dose given in smaller fractions is beneficial. Surgery generally comprises total nephrectomy, but there is international debate about the value of partial nephrectomy. In bilateral disease or in patients with a predisposition syndrome and at increased risk of developing metachronous tumours, an attempt is made to preserve renal tissue by performing partial nephrectomy.

In this review, we address the major late consequences that occur in survivors of childhood renal tumours, including late mortality, cardiovascular, renal, reproductive function and development of second malignant neoplasms (SMN). Late effects of treatment are defined as clinical or subclinical consequences that persist or appear >5 years after diagnosis.

Late mortality (mortality occurring >5 years from diagnosis)

Mortality studies are robust and largely predate comprehensive morbidity studies. They lead the way to understanding the late effects of cancer treatment, and for this reason, they are discussed first. Three large epidemiological studies have been published in the last few years. The multicentre American Childhood Cancer Survivors Study (CCSS), the National Wilms Tumor Study Group (based in North America) with patient overlap with CCSS and the population-based British Childhood Cancer Survivors Study (BCCSS), all of which assessed causes of death in patients who had survived 5 years from their cancer diagnosis [35]. These studies showed that although long-term outcome is excellent, renal cancer survivors are at risk of premature death. Mortality studies in the UK and USA identified an overall standardised mortality ratio of 5.8–4.9 in patients treated from 1940 to 1991 and 1969 to 1995, respectively [3, 5]. Early deaths (<5 years from diagnosis) are mainly due to disease relapse compared with late mortality, for which studies identify a crossover of causes, with fewer deaths due to disease recurrence and more due to treatment-related causes. Over time from diagnosis, the risk of premature death fell from a 13-fold at 5–10 years from diagnosis to 5-fold at 30 years compared with age- and sex-matched peers in the general population [4]. Encouragingly, there is a trend that more contemporary patients may be at less risk of premature death [3]. Analysis of the causes of late deaths across all reports identified SMN as the leading cause, followed by cardiac and pulmonary disease [35].

Overall late morbidity

Following on from the mortality studies, two studies reported on overall morbidity: a patient questionnaire study from the American CCSS [6] assessed 1,256 WT survivors diagnosed between1970 and 1986, and Greenan et al. published a smaller study using clinically obtained data in 189 survivors from a single centre who were diagnosed between 1966 and 2004 [7]. In the latter study, 29% of survivors had no adverse effects, and 12% demonstrated a high or severe burden of adverse effects. The authors emphasised the increased risk of cardiovascular problems after anthracyclines and thoracic and/or abdominal radiation, with relative risks (RR) of 3.55 [95% confidence interval (CI) 1.52–8.20] and 2.36 (95% CI 1.69–3.29), respectively. The large multicentre study reported a cumulative incidence of severe chronic health conditions of 24% at 25 years. Interestingly, compared with sibling controls, there was no difference in mental health status, socioeconomic outcome and health-care use [6].

Cardiotoxicity

Cardiotoxicity is a leading cause of morbidity due to the use of anthracyclines (doxorubicin is commonly used) and radiation when the radiation field involves the heart. Anthracyclines were added to the treatment regimen in the late 1970s, with the immediate benefit of increasing survival in high-stage disease. Since their early use, there has been an appreciation of their preferential myocyte toxicity causing cardiomyopathy. Clinical heart failure is the most common presentation, which may occur acutely or many years from the completion of treatment [8, 9]. In a single-centre British study, cardiac function was evaluated 1.0–18.8 (mean 7.1) years after completion of treatment in 97 children whose therapy for WT included an anthracycline (mean cumulative dose 303 mg/m2) [10]. Subclinical cardiac abnormalities, identified by detailed echocardiograms, were found in 25% of patients. In multivariate analysis that included cardiac radiation (from lung and left-flank radiation), only increasing cumulative dose and dose intensity were significant risk factors for impaired cardiac function. With longer follow-up, an American study reported that the cumulative risk of clinical congestive heart failure 20 years after diagnosis was 4.4% in relapse-free WT patients whose treatment included anthracyclines with or without cardiac irradiation, and this increased markedly to17.4% in survivors of relapsed WT [11, 12]. A number of studies have highlighted the progressive nature of the damage, with an increasing life-long risk of developing clinical cardiac dysfunction, which may necessitate a cardiac transplant [1315]. Follow-up involves regular echocardiography, the frequency of which depends upon the possible risk of progressive disease [16].

Renal disease

As expected, there is a degree of renal impairment in survivors of renal cancer, although recent studies are reassuring [17]. Renal function can be affected by all treatment modalities: surgery reducing the renal mass, radiation to the remaining kidney(s) or nephrotoxic chemotherapeutic agents (Ifosphamide, carboplatin), in addition to genetic conditions. Encouragingly, renal disease is not a major issue for uncomplicated unilateral renal tumours. Patients at maximum risk of end-stage renal disease are those with bilateral disease, occurring either synchronously and metachronously or in association with a WT-1 mutation [WT–aniridia syndrome (WAGR), Denys–Drash and the rarer Frasier syndrome] [18]. A study using the National Wilms Tumour Study Group database between 1969 and 1994 identified a cumulative incidence of end-stage renal failure at 20 years in unilateral disease to be 0.6% when there was no evidence of WT-1 mutation or genitourinary anomalies. However, renal failure occurred in 74% of those with accompanying Denys–Drash syndrome, 36% in WAGR patients and 7% in male patients with cryptorchidism or hypospadias. In those with bilateral disease, end-stage renal disease occurred in 12%, with a higher incidence in WAGR patients of 90%, and 20% in males with associated genitourinary anomalies [18]. Interestingly, patients with intralobar nephrogenic rests identified in the healthy part of the kidney but with no known predisposition had a slightly increased risk of renal disease compared with those with healthy kidney surrounding the WT [19].

Survivors of childhood cancer who have undergone nephrectomy or bilateral partial nephrectomy may be at risk of late hyperfiltration injury and/or hypertension. Compensatory hypertrophy of the remaining kidney is a well-documented finding after nephrectomy [20, 21]. Although this adaptation may initially increase glomerular filtration capacity, there may be a later development of glomerulosclerosis [22, 23], and interstitial injury [23] may ultimately lead to renal function deterioration. The prevalence of microalbuminuria, which is indicative of glomerular hyperfiltration, following nephrectomy for WT is less clear and has been reported to range from 5% to 84% [24, 25]. Diastolic hypertension has been reported, although the incidence is variable: from 0–7% [18, 20, 24]. In a large analysis of 1,171 children treated for WT whose blood pressure was measured 5 years after diagnosis, 83 (7%) had a diastolic blood pressure >95th percentile for age [24]. The relative contribution of nephrectomy to this complication was unclear because a substantial proportion of patients with diastolic hypertension had also received abdominal radiotherapy.

Ifosfamide has been used in some protocols for first-line treatment in high-stage disease and in relapse protocols. This alkylating agent is nephrotoxic, causing both tubular (Fanconi’s syndrome) and glomerular damage [26, 27]. The risk of developing nephrotoxicity is related to the total cumulative dose of Ifosfamide (>60–100 g/m2) [2527] and to patient-related factors such as the presence of a single kidney [28], renal irradiation [29] and young age [3032]. Clearly, patients with WT are at particular risk. The prognosis of the nephropathy is variable, with some patients no longer requiring electrolyte supplementation and others progressing to renal failure [33]. In tumour relapse, patients can be salvaged with a combination of agents—ifosfamide, carboplatin and etoposide, which is nephrotoxic—and careful monitoring is required [34]. The recommendations for survivor follow-up are regular urinanalysis and blood pressure monitoring, with more intensive follow-up in the at-risk patients [17].

Fertility and pregnancy outcomes

Of great concern to survivors is the issue of fertility and whether their offspring will be affected by their previous treatment. The first-line chemotherapy used, in general, does not affect either ovarian reserve or male fertility. Cyclophosphamide used in high-risk patients may affect sperm count, but it is unlikely to cause ovarian failure [35]. Ifosfamide can affect fertility, but the doses used in the relapse protocols are lower than shown to cause gonadal damage [36]. Abdominal radiation has a more detrimental effect on female reproduction. Radiation to the abdomen usually involves the pelvis, and therefore, the ovaries and uterus may be in the field and at risk of damage. Whole-abdomen radiation usually results in primary ovarian failure or premature menopause. Several studies demonstrated that the offspring of women who received flank radiation for WT were more likely to have a birthweight <2,500 g, prematurity and foetal malposition than were those born to women whose protocol treatment did not include flank irradiation [3739]. An added complication is the unusual finding that genitourinary anomalies are known to occur in WT patients, including Müllerian duct anomalies, with septate/unicornuate uteri occurring [39, 40]. Nicholson et al. reported uterine abnormalities in 8% (2 of 24) of female WT patients, one of whom had WAGR syndrome [40].

Second malignant neoplasms

The occurrence of second tumours within the cancer population, either benign or malignant, is a well-recognised late sequel of therapy, and WT survivors are no exception. The less serious occurrence of osteochondromas, or benign bone tumours, may be associated with radiation of the epiphysis of growing bone. These tumours can cause pain, affect function and be unsightly, requiring surgical intervention [4143]. Interestingly, these tumours have been reported in unirradiated WT patients, some of whom had a family history of multiple exostoses [44, 45]. Patients exposed to radiotherapy, certain chemotherapy agents or with a known familial cancer predisposition syndrome have all been demonstrated to have an increased risk of second cancers. Studies across a number of countries have given a range of cumulative incidence of 0.65–0.8% at 10 years, increasing to 4.8–7.0% at 30 years, with no obvious plateau. Radiation therapy has been consistently shown to be an important contributory factor in the excess risk of subsequent cancers. Breslow et al. reported that 73% of second solid tumours occurred within the radiotherapy field, and they found clear evidence of an increase in the risk of second cancer with increasing doses of radiation [46]. This is supported by Taylor et al., who reported that 35 of 39 solid tumours were within the radiation field and the majority had an estimated radiation dose of >25 Gy [47]. An international analysis of SMN in WT survivors showed a consistent rate across countries [48].

Tumour types vary; they include bone and soft-tissue sarcomas, breast cancer, lymphoma, tumours of the digestive tract and melanoma [46, 47]. Acute leukaemias also occur, particularly in patients treated in the modern era. It has been postulated that this may be due to more intensive chemotherapy regimens [48].

Other late effects

Radiotherapy causes disruption of tissue growth and therefore these young patients, in addition to the main late effects, do exhibit poor development of both muscle and bone within the radiation field. For example, patients who received flank radiation have reduced final height because of poor growth of the irradiated spine, with the degree of shortening depending on the dose and age at treatment. In addition, there is soft-tissue hypoplasia with truncal asymmetry when flank radiation has been given [49, 50]. In the recent BCCSS study, the Physical Component Score (PCS) analysis showed a normal result in the younger age range (16–19 years) but worsened with age so that survivors >35 years showed a significant difference in mean PCS score, with values of −3.0 compared with population norms. Females performed consistently worse than males. Twenty-five percent stated they could not walk a mile, with 9% being unable to walk 100 yards [51]. From a socioeconomic aspect, WT survivors compare well with the general population with comparable educational attainments [51], employment [52] and mental health outcomes [51, 53, 54].

Conclusions

In this review, we addressed the potential late consequences of successful treatment for childhood renal tumours. It is important to view these late consequences within the context of the wider clinical picture. WT treatment has been a success story, and >80% of children diagnosed with WT can look forward to long-term survivorship. The late complications are a consequence of the type and intensity of treatment required, which in turn reflects the nature and extent of the original tumour. The late effects reported here are a reflection of treatments given over many decades, and the next generation of treatment protocols hopefully will cause less problems as international groups design new strategies to try to reduce late sequelae. From a nephrology perspective, the majority of survivors have few renal problems. In the future, genetic research may well identify those at particular risk who will then require specialised nephrology follow-up. For all survivors, there is a need for long-term follow-up programmes to be developed, with individualised follow-up plans designed to optimise the patient’s knowledge of long-term risks, in addition to providing specific clinical surveillance to achieve early diagnosis of sequelae and determine effective management [17, 55].

Questions (Answers appear following the reference list)

  1. Which treatment modality is responsible for the majority of late effects?
    1. Surgery
    2. Radiotherapy
    3. Alkylating agents
    4. Anthracyclines
    5. Carboplatin
  2. Which subset of patients are at significant risk of renal failure?
    1. Unilateral disease with genitourinary abnormalities
    2. Beckwith–Wiedemann syndrome
    3. Bilateral disease
    4. Treatment with anthracyclines
    5. WAGR patients
  3. Which of the following is true about anthracyclines?
    1. Cause stunted growth
    2. Late effect is associated with total dose administered
    3. Cardiotoxicity seen is commonly due to dysrhythmias
    4. After the initial hit, there is no progression of cardiac disease
  4. Which of the following is true about second tumours?
    1. Always malignant
    2. Generally occur outside the radiation field
    3. Occur many decades from the original treatment
    4. Caused primarily by chemotherapy
  5. Which of the following is true about effects on fertility?
    1. Males are more at risk of infertility than females after treatment for Wilms tumour
    2. Etoposide is the drug commonly associated with infertility
    3. The foetus is at risk of hydramnios
    4. Premature births occur more frequently in patients who have not received radiation
    5. Offspring are generally not at risk of developing WT

Footnotes

Answers:

1. b

2. e

3. b

4. c

5. e

References

1. Kroll ME, Passmore SJ, Stiller CA. Childhood cancer - UK. In: Toms JR, editor. CancerStats Monograph 2004. London: Cancer Research UK; 2004. pp. 63–72.
2. Pritchard-Jones K, Pritchard J. Success of clinical trials in childhood Wilms tumour around the world. Lancet. 2004;364:1468–1470. doi: 10.1016/S0140-6736(04)17289-9. [PubMed] [Cross Ref]
3. Cotton CA, Peterson S, Norkool PA, Takashima J, Grigoriev Y, Green DM, Breslow NE. Early and late mortality after diagnosis of Wilms tumor. J Clin Oncol. 2009;27:1304–1309. doi: 10.1200/JCO.2008.18.6981. [PMC free article] [PubMed] [Cross Ref]
4. Armstrong GT, Liu Q, Yasui Y, Neglia JP, Leisenring W, Robison LL, Mertens AC. Late mortality among 5-year survivors of childhood cancer: a summary from the childhood cancer survivor study. J Clin Oncol. 2009;27:2328–2338. doi: 10.1200/JCO.2008.21.1425. [PMC free article] [PubMed] [Cross Ref]
5. Reulen RC, Winter DL, Frobisher C, Lancashire ER, Stiller CA, Jenney ME, Skinner R, Stevens MC, Hawkins MM. British childhood cancer survivor study steering group long-term cause-specific mortality among survivors of childhood cancer. JAMA. 2010;304:172–179. doi: 10.1001/jama.2010.923. [PubMed] [Cross Ref]
6. Termuhlen AM, Tersak JM, Liu Q, Yasui Y, Stovall M, Weathers R, Deutsch M, Sklar CA, Oeffinger KC, Armstrong G, Robison LL, Green DM (2011) Twenty-five year follow-up of childhood Wilms tumor: a report from the childhood cancer survivor study Pediatr Blood Cancer. [PubMed]
7. Geenen MM, Cardous-Ubbink MC, Kremer LC, Bos C, Pal HJ, Heinen RC, Jaspers MW, Koning CC, Oldenburger F, Langeveld NE, Hart AA, Bakker PJ, Caron HN, Leeuwen FE. Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA. 2007;297:2705–2715. doi: 10.1001/jama.297.24.2705. [PubMed] [Cross Ref]
8. Goorin AM, Chauvenet AR, Perez-Atayde AR. Initial congestive heart failure six to ten years after doxorubicin chemotherapy for childhood cancer. J Pediat. 1996;116:144–147. doi: 10.1016/S0022-3476(05)81668-3. [PubMed] [Cross Ref]
9. Steinherz LJ, Steinherz G, Tan CJ. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991;266:1672–1677. doi: 10.1001/jama.1991.03470120074036. [PubMed] [Cross Ref]
10. Sorensen K, Levitt G, Sebag-Montefiore D, Bull C, Sullivan I. Cardiac function in Wilms tumor survivors. J Clin Oncol. 1995;13:1546–1556. [PubMed]
11. Green DM, Grigoriev YA, Nan B, Takashima JR, Norkool PA, D’Angio GJ, Breslow NE. Congestive heart failure after treatment for Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol. 2001;19:1926–1934. [PubMed]
12. Green DM, Grigoriev YA, Nan B, Takashima JR, Norkool PA, D'Angio GJ, Breslow NE. Correction to “Congestive heart failure after treatment for Wilms tumor” J Clin Oncol. 2003;21:2447–2448. doi: 10.1200/JCO.2003.99.005. [PubMed] [Cross Ref]
13. Pein F, Sakiroglu O, Dahan M, Lebidois J, Merlet P, Shamsaldin A, Villain E, Vathaire F, Sidi D, Hartmann O. Cardiac abnormalities 15 years and more after Adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. Br J Cancer. 2004;91:37–44. doi: 10.1038/sj.bjc.6601904. [PMC free article] [PubMed] [Cross Ref]
14. Sorensen K, Levitt GA, Bull C, Dorup I, Sullivan ID. Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer. 2003;97:1991–1998. doi: 10.1002/cncr.11274. [PubMed] [Cross Ref]
15. Levitt G, Anazodo A, Burch M, Bunch K. Cardiac or cardiopulmonary transplantation in childhood cancer survivors: An increasing need? Eur J Cancer. 2009;45:3027–3034. doi: 10.1016/j.ejca.2009.08.006. [PubMed] [Cross Ref]
16. Bailey S, Roberts A, Brock C, Price L, Craft AW, Kilkarni R, Lee RE, Skillen AW, Skinner R. Nephrotoxicity in survivors of Wilms tumours in the North of England. Br J Cancer. 2002;87:1092–1098. doi: 10.1038/sj.bjc.6600608. [PMC free article] [PubMed] [Cross Ref]
17. Skinner R, Levitt G, Wallace WH. Therapy based LTFU practice statement UKCCSG (2005) www.ukccsg.org.uk/public/followup/PracticeStatement/index.html.
18. Breslow NE, Collins AJ, Ritchey ML, Grigoriev YA, Peterson SM, Green DM. End stage renal disease in patients with Wilms tumor: results from the National Wilms Tumor Study Group and the United States Renal Data System. J Urol. 2005;174:1972–1975. doi: 10.1097/01.ju.0000176800.00994.3a. [PMC free article] [PubMed] [Cross Ref]
19. Breslow NE, Takashima JR, Ritchey ML, Strong LC, Green DM. Renal failure in the Denys-Drash and Wilms tumor-aniridia syndromes. Cancer Res. 2000;60:4030–4032. [PubMed]
20. Levitt GA, Yeomans E, Dicks Mireaux C, Breatnach F, Kingston J, Pritchard J. Renal size and function after cure of Wilms tumour. Br J Cancer. 1992;66:877–882. doi: 10.1038/bjc.1992.378. [PMC free article] [PubMed] [Cross Ref]
21. Gutierrez-Millet V, Nieto J, Praga M, Usera G, Martinez MA, Morales JM. Focal glomerulosclerosis and proteinuria in patients with solitary kidneys. Arch Intern Med. 1986;146:705–709. doi: 10.1001/archinte.1986.00360160127017. [PubMed] [Cross Ref]
22. Welch TR, McAdams AJ. Focal glomerulosclerosis as a late sequela of Wilms tumor. J Pediatr. 1986;108:105–109. doi: 10.1016/S0022-3476(86)80781-8. [PubMed] [Cross Ref]
23. Mitus A, Tefft M, Fellers FX. Long term follow up of renal function of 108 children who underwent nephrectomy for malignant disease. Pediatrics. 1969;44:912–921. [PubMed]
24. Finklestein JZ, Norkool P, Green DM, Breslow N, D'Angio GJ. Diastolic hypertension in Wilms tumor survivors: a late effect of treatment? A report from the National Wilms Tumor Study Group. Am J Clin Oncol. 1993;16:201–205. doi: 10.1097/00000421-199306000-00003. [PubMed] [Cross Ref]
25. Srinivas M, Agarwala S, Padhy AK, Gupta AK, Bajpai M, Bhatnagar V, Gupta DK, Mitra DK. Somatic growth and renal function after unilateral nephrectomy for Wilms tumor. Pediatr Surg Int. 1998;14:185–188. doi: 10.1007/s003830050482. [PubMed] [Cross Ref]
26. Loebstein R, Koren G. Ifosfamide-induced nephrotoxicity in children: critical review of predictive risk factors. Pediatrics. 1998;101:E8. doi: 10.1542/peds.101.6.e8. [PubMed] [Cross Ref]
27. Skinner R, Cotterill SJ, Stevens MC. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children’s Cancer Study Group. Br J Cancer. 2000;82:1636–1645. doi: 10.1054/bjoc.2000.1214. [PMC free article] [PubMed] [Cross Ref]
28. Rossi R, Godde A, Kleinebrand M, Riepenhausen M, Boos J, Ritter J, Jürgens H. Unilateral nephrectomy and cisplatin as risk factors of ifosfamide induced nephrotoxicity: analysis of 120 patients. J Clin Oncol. 1994;12:159–165. [PubMed]
29. Fels LM, Bokemeyer C, Rhee J, Schmoll HJ, Stolte H. Evaluation of late nephrotoxicity in long-term survivors of Hodgkin’s disease. Oncology. 1996;53:73–78. doi: 10.1159/000227539. [PubMed] [Cross Ref]
30. Stohr W, Paulides M, Bielack S, Jurgens H, Treuner J, Rossi R, Langer T, Beck JD. Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System. Pediatr Blood Cancer. 2007;48:447–452. doi: 10.1002/pbc.20858. [PubMed] [Cross Ref]
31. Aleksa K, Woodland C, Koren G. Young age and the risk for ifosfamide-induced nephrotoxicity: a critical review of two opposing studies. Pediatr Nephrol. 2001;16:1153–1158. doi: 10.1007/s004670100053. [PubMed] [Cross Ref]
32. Loebstein R, Atanackovic G, Bishai R, Wolpin J, Khattak S, Hashemi G, Gobrial M, Baruchel S, Ito S, Koren G. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children. J Clin Pharmacol. 1999;39:454–461. [PubMed]
33. Skinner R, Parry A, Price L, Cole M, Craft AW, Pearson AD. Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose. Pediatr Blood Cancer. 2010;54:983–989. doi: 10.1002/pbc.22364. [PubMed] [Cross Ref]
34. Daw NC, Gregornik D, Rodman J, Marina N, Wu J, Kun LE, Jenkins JJ, McPherson V, Wilimas J, Jones DP. Renal function after ifosfamide, carboplatin and etoposide (ICE) chemotherapy, nephrectomy and radiotherapy in children with Wilms tumour. Eur J Cancer. 2009;45:99–106. doi: 10.1016/j.ejca.2008.09.017. [PMC free article] [PubMed] [Cross Ref]
35. Kenney LB, Kenney LB, Laufer MR, Grant FD, Grier H, Diller L. High risk of infertility and long term gonadal damage in males treated with high dose cyclophosphamide for sarcoma during childhood. Cancer. 2001;91:613–621. doi: 10.1002/1097-0142(20010201)91:3<613::AID-CNCR1042>3.0.CO;2-R. [PubMed] [Cross Ref]
36. Williams D, Crofton PM, Levitt G. Does ifosfamide affect gonadal function? Pediatr Blood Cancer. 2008;50:347–351. doi: 10.1002/pbc.21323. [PubMed] [Cross Ref]
37. Green DM, Lange JM, Peabody EM, Grigorieva NN, Peterson SM, Kalapurakal JA, Breslow NE. Pregnancy outcome after treatment for Wilms tumor: a report from the national Wilms tumor long-term follow-up study. J Clin Oncol. 2010;28:2824–2830. doi: 10.1200/JCO.2009.27.2922. [PMC free article] [PubMed] [Cross Ref]
38. Li FP, Gimbrere K, Gelber RD, Flamant F, Green DM, Heyn RM, Meadows AT. Outcome of pregnancy in survivors of Wilms tumor. JAMA. 1987;257:216–219. doi: 10.1001/jama.1987.03390020082031. [PubMed] [Cross Ref]
39. Byrne J, Mulvihill JJ, Connelly RR, Austin DA, Holmes GE, Holmes FF, Latourette HB, Meigs JW, Strong LC, Myers MH. Reproductive problems and birth defects in survivors of Wilms tumor and their relatives. Med Pediatr Oncol. 1988;16:233–240. doi: 10.1002/mpo.2950160403. [PubMed] [Cross Ref]
40. Nicholson HS, Blask AN, Markle BM, Reaman GH, Byrne J. Uterine anomalies in Wilms tumor survivors. Cancer. 1996;78:887–891. doi: 10.1002/(SICI)1097-0142(19960815)78:4<887::AID-CNCR28>3.0.CO;2-Q. [PubMed] [Cross Ref]
41. Libshitz HI, Cohen MA. Radiation induced osteochondromas. Radiology. 1982;142:643–647. [PubMed]
42. Jaffe N, Ried HL, Cohen M, McNeese MD, Sullivan MP. Radiation induced osteochondroma in long-term survivors of childhood cancer. Int J Radiat Oncol Biol Phys. 1983;9:665–670. doi: 10.1016/0360-3016(83)90232-8. [PubMed] [Cross Ref]
43. Tsuchiya H, Morikawa S, Tomita K. Osteosarcoma arising from a multiple exostosis lesion: case report. Jpn J Clin Oncol. 1990;20:296–298. [PubMed]
44. Walker DA, Dillon M, Levitt G, Cervera A, Shaw D, Pritchard J. Mulitple exotosis (osteochondroma) and Wilms tumour - a possible association. Med Pediatr Oncol. 1992;20:360–361. doi: 10.1002/mpo.2950200421. [PubMed] [Cross Ref]
45. Jennes I, Pedrini E, Zuntini M, Mordenti M, Balkassmi S, Asteggiano CG, Casey B, Bakker B, Sangiorgi L, Wuyts W. Multiple osteochondromas: mutation update and description of the multiple osteochondromas mutation database (MOdb) Hum Mutat. 2009;30:1620–1627. doi: 10.1002/humu.21123. [PubMed] [Cross Ref]
46. Breslow NE, Takashima JR, Whitton JA, Moksness J, D'Angio GJ, Green DM. Second malignant neoplasms following treatment for Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol. 1995;13:1851–1859. [PubMed]
47. Taylor AJ, Winter DL, Pritchard-Jones K, Stiller CA, Frobisher C, Lancashire ER, Reulen RC, Hawkins MM. Second primary neoplasms in survivors of Wilms tumour-a population-based cohort study from the British Childhood Cancer Survivor Study. Int J Cancer. 2008;122:2085–2093. doi: 10.1002/ijc.23333. [PubMed] [Cross Ref]
48. Breslow NE, Lange JM, Friedman DL, Green DM, Hawkins MM, Murphy MFG, Neglia JP, Olsen JH, Peterson SM, Stiller CA, Robison LL. Secondary malignant neoplasms following Wilms Tumor: an International Collaborative Study. Int J Cancer Int J Cancer. 2010;127:657–666. [PMC free article] [PubMed]
49. Shalet SM, Gibson B, Swindell R, Pearson D. Effect of spinal irradiation on growth. Arch Dis Child. 1987;62:461–464. doi: 10.1136/adc.62.5.461. [PMC free article] [PubMed] [Cross Ref]
50. Makiprnaa A, Keikkila JT, Merikanto J, Marttinen E, Siimes MA. Spinal deformity induced by radiotherapy for solid tumours in childhood: a long term study. Eur J Pediat. 1993;152:197–200. doi: 10.1007/BF01956143. [PubMed] [Cross Ref]
51. Reulen RC, Winter DL, Lancashire ER, Zeegers MP, Jenney ME, Walters SJ, Jenkinson C, Hawkins MM. Health-status of adult survivors of childhood cancer: a large-scale population-based study from the British Childhood Cancer Survivor Study. Int J Cancer. 2007;121:633–640. doi: 10.1002/ijc.22658. [PubMed] [Cross Ref]
52. Pang JW, Friedman DL, Whitton JA, Stovall M, Mertens AC, Robison LL, Weiss NS. Employment status among adult survivors in the Childhood Cancer Survivor Study. Pediatr Blood Cancer. 2008;50:104–110. doi: 10.1002/pbc.21226. [PubMed] [Cross Ref]
53. Gurney JG, Krull KR, Kadan-Lottick N, Nicholson HS, Nathan PC, Zebrack B, Tersak JM, Ness KK. Social outcomes in the Childhood Cancer Survivor Study cohort. J Clin Oncol. 2009;27:2390–2395. doi: 10.1200/JCO.2008.21.1458. [PMC free article] [PubMed] [Cross Ref]
54. Lahteenmaki PM, Sankila R, Pukkala E, Kyyronen P, Harila-Saari A. Scholastic achievement of children with lymphoma or Wilms tumor at the end of comprehensive education - a nationwide, register-based study. Int J Cancer. 2008;123:2401–2405. doi: 10.1002/ijc.23753. [PubMed] [Cross Ref]
55. National Cancer Survivorship initiative http://www.ncsi.org.uk/

Articles from Springer Open Choice are provided here courtesy of Springer